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Anti-infectives
Safety of neuraminidase 
inhibitors for influenza
Mark Jones† & Chis Del Mar
†University of Queensland, Princess Alexandra Hospital, School of Population Health, Woolloongabba, 
Queensland 4102, Australia
Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treat-
ment of, and protection from, influenza. The safety of these compounds has
been assessed in systematic reviews. However, the data presented are some-
what limited by the paucity of good quality adverse event data available. The
majority of safety outcomes are based on evidence from just one or two ran-
domised controlled trials. The results of the systematic reviews suggest that
neuraminidase inhibitors have a reasonable side effect and adverse effect
profile if they are to be used to treat or protect patients against a life-threat-
ening disease. However, if these compounds are to be prescribed in situations
in which avoidance of inconvenience or minor discomfort is hoped for, then
the balance of harms to benefits will be more difficult to judge.
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1. Introduction
1.1 Influenza the illness
Although the influenza virus usually causes only minor symptoms (headache, runny
nose, dry cough, fever, muscle pain and sore throat) for about one week, and most
recover without requiring treatment, it can be fatal. People at threat are the very
young, the elderly and those with comorbidity, especially if the immune system is
compromised, including almost any serious health condition, such as cancer, lung
disease, heart or kidney problems. The mode of death often includes dehydration
and pneumonia. Three to five million cases of influenza lead to the death of between
250,000 – 500,000 people annually [101].
Influenza is so infectious it gives rise to seasonal epidemics in which 5 – 20% of
the population become infected. The disease is spread from person to person via res-
piratory droplets caused by coughing and sneezing, or by fomite transmission
(in which the virus is picked up on fingers and inadvertently transferring it to the
respiratory mucosa). The incubation period for influenza is typically 1 – 4 days.
Adults are able to infect others from a day before symptoms develop to ∼ 5 days
afterwards, although children can do so for longer – up to 10 days or more.
Influenza can be classified in several ways: the two main types (Influenza A and B)
and several subtypes based on the detection of two viral surface proteins; for example,
Type A(H3N2) and A(H1N1). H represents haemagglutinin and N neuraminidase.
The haemagglutinin antigen enables the influenza virus to enter human respiratory
epithelium cells, and the neuraminidase antigen allows the release of newly replicated
viral particles from infected cells. Instability of these proteins leads to minor genetic
changes in the structure of the viruses, called antigenic drift, generating new viral
strains, sufficiently different from previously exposed strains to require new exposure
to the immune system to generate protection (unlike, for example, most childhood
viral infections, which once encountered are never experienced again). This is the
cause of seasonal influenza. Major genetic changes, antigenic shift, occur infrequently
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(three times in the last century) and these give rise to global
pandemics that have claimed the lives of millions, including
the young and healthy. In modern epidemics, most influ-
enza-related deaths are due to exacerbation of underlying car-
diopulmonary disease, and pneumonia is a relatively minor
contributor. However, this ratio is reversed in pandemic years
when most deaths are due to pneumonia.
1.2 Neuraminidase inhibitors
Neuraminidase inhibitors differ from the pre-existing antiviral
agents, amantadine and rimantadine, which are only effective
in the treatment of type A influenza. Amantadine and riman-
tadine have a stronger side effect profile, including severe
adverse reactions, and there are problems with the induction
of resistance with Influenza Type A.
Neuraminidase inhibitors can be used for treatment of, as
well as the prophylaxis against influenza type A and type B.
They block the activity of the viral neuraminidase
enzyme needed to enable new viral particles from being
released out of infected cells. There are two neuraminidase
inhibitors currently available: zanamivir (Relenza® made by
Glaxo Wellcome), a powder that is normally inhaled, and
oseltamivir (Tamiflu®, co-developed by Gilead Sciences, and
Hoffmann-La Roche), an oral agent available as both a sus-
pension and a tablet. In addition, there are other neuramini-
dase inhibitors being developed that could potentially be
available in the not-too-distant future.
The FDA has approved the use of oseltamivir for the treat-
ment of uncomplicated influenza in patients aged ≥ 1 year
whose symptoms have not lasted > 2 days, and for the preven-
tion of influenza in adults and children aged ≥ 1 year. How-
ever, it acknowledges that treatment efficacy has not been
established in subjects with chronic cardiac disease or respira-
tory disease and prevention efficacy has not been established
in immunocompromised patients. Oseltamivir is not
approved for infants aged < 1 year because preclinical studies
in juvenile rats have found extremely toxic levels of drug in
the brains of the rats after application of a single dose. This is
most probably because of permeability of the immature
blood–brain barrier [102]. Zanamivir has been approved for
persons aged ≥ 7 years for the treatment of uncomplicated
influenza virus but not for use in prevention of influenza
(prophylaxis). It is not recommended for people with under-
lying respiratory disease such as asthma as some people with
these conditions have experienced serious side effects such as
wheezing and shortness of breath and it has not been shown
to be effective in this population [103]. The European Medi-
cines Agency (EMA) has given a similar indication for treat-
ment with oseltamivir, although their indication for
prevention differs. Postexposure prevention is indicated for
adults and adolescents aged ≥ 13 years, whereas seasonal pre-
vention of influenza should only be considered in adults and
adolescents aged ≥ 13 years in exceptional situations [104].
Zanamivir is indicated for treatment of adults and adolescents
aged ≥ 12 years, but is not yet approved for prophylaxis [105].
It is the safety profile of neuraminidase inhibitors which is
the subject of this review. The review is based primarily on
data from the most recent systematic review of the efficacy
and safety of antiviral agents for the treatment and preven-
tion of influenza in healthy adults [1], and a Cochrane sys-
tematic review of neuraminidase inhibitors for preventing
and treating influenza in children [2]. It should be noted that
the systematic review for children was not able to identify
any prophylaxis studies of neuraminidase inhibitors accepta-
ble for inclusion, so safety data for oseltamivir or zanamivir
in a prophylaxis role for children is not presented in this
review. A systematic review of randomised, controlled trials is
generally regarded as the highest level of evidence attainable
for healthcare interventions. In addition, it has been reported
that non-randomised studies generally tend to underestimate
the risk of harms from medical interventions compared with
randomised studies [3].
2. Safety profile of oseltamivir
According to the manufacturer, the adverse events occurring
more frequently in patients taking oseltamivir compared to
placebo are nausea, vomiting, bronchitis, insomnia and ver-
tigo for adults in treatment studies; vomiting, abdominal
pain, epistaxis, ear disorder and conjunctivitis for paediatric
patients in treatment studies; and nausea, vomiting, diar-
rhoea, abdominal pain, dizziness, headache, insomnia, ver-
tigo and fatigue for adults and adolescents in prophylaxis
studies [106]. The following data comes from the most recent
systematic review of the efficacy and safety of antiviral agents
for the treatment and prevention of influenza [1] and a
Cochrane systematic review of neuraminidase inhibitors for
preventing and treating influenza in children [2].
2.1 Prophylaxis in adults
In a prophylaxis role, oral oseltamivir at 75 mg/day is asso-
ciated with significantly more nausea compared to placebo
(OR: 1.8, 95% CI: 1.1 – 2.9). The number of people tak-
ing 75 mg/day that would result in one additional case of
nausea (‘number needed to harm’) is 20 (95% CI: 13 – 63).
Oral oseltamivir at the higher dose of 150 mg per day is
also associated with significantly more nausea compared
with placebo (OR: 2.3, 95% CI: 1.3 – 3.9). The number
needed to harm for the higher dose is 13 (95% CI: 9 – 33).
The increased vomiting associated with oseltamivir use is
not significantly different from that experienced by those
taking placebo: oral oseltamivir at 75 mg/day, OR: 2.3,
(95% CI: 0.9 – 6.0), at 150 mg/day, OR: 3.6, (95% CI:
0.8 – 15.8). Other reported adverse events are similarly not
significantly different between oseltamivir at 75 mg/day
and placebo: diarrhoea (OR: 0.6, 95% CI: 0.3 – 1.2),
abdominal pain (OR: 1.0, 95% CI: 0.5 – 2.0) and other
adverse events (OR: 1.0, 95% CI: 0.6 – 1.6), Table 1. With-
drawals due to gastrointestinal events were too infrequent
to provide meaningful results.
Jones & Del Mar
Expert Opin. Drug Saf. (2006) 5(5) 3
2.2 Treatment in adults
In a treatment role, there is insufficient evidence to confirm
oral oseltamivir is associated with increased adverse events
compared to placebo. It appears that 150 – 300 mg daily may
be associated with more nausea than placebo, but any differ-
ences are not statistically significant (OR: 1.8, 95% CI:
0.7 – 4.4). Other adverse events compared included: cough
(OR: 1.3, 95% CI: 0.5 – 3.2), headache (OR: 1.0,  95% CI:
0.5 – 2.0), diarrhoea (OR: 0.6,  95% CI 0.3 – 1.1), nasal
symptoms (congestion, rhinitis, dry or sore throat) (OR: 0.9,
95% CI: 0.5 – 1.4) and all types of adverse events (OR: 0.7,
95% CI: 0.4 – 1.1), Table 2.
2.3 Treatment in children
Oral oseltamivir in a treatment role in children is associated with
significantly more vomiting compared with placebo (OR: 1.7,
95% CI: 1.2 – 2.5), resulting in a number needed to harm of 18
(95% CI: 11 – 67). Surprisingly there appears to be no such
effect for nausea (OR: 0.8,  95% CI: 0.4 – 1.5). Other reported
adverse events are similar for oseltamivir and placebo groups: any
adverse event (OR: 0.9,  95% CI: 0.7 – 1.1), serious adverse
events (OR: 2.0,  95% CI: 0.6 – 6.7), adverse events leading to
study withdrawal (OR: 1.0,  95% CI: 0.4 – 2.7), and diarrhoea
(OR: 0.8,  95% CI: 0.5 – 1.3), Table 3.
3. Safety profile of zanamivir
The manufacturer reports the following side effects from zan-
amivir: nausea, diarrhoea and sinusitis. But the incidence of
these adverse events is reported similar for treated patients
using active drug and placebo. Bronchospasm and decline in
lung function has been reported by some patients receiving
zanamivir, mainly but not exclusively, in patients with under-
lying airway disease (such as asthma or chronic obstructive
pulmonary disease) [107].
3.1 Prophylaxis in adults
The most recent systematic review of the efficacy and safety of
antiviral agents for the treatment and prevention of influenza
did not report on adverse events for zanamivir in a prophy-
laxis role [1]. Therefore, data from a previous systematic review
are presented [4]. All adverse events were pooled and the pro-
portions of individuals with an adverse event in the two
groups were: zanamivir: 7.5% (95% CI: 6.2 – 9.2%) versus
placebo: 7.8% (95% CI: 6.4 – 9.7%).
3.2 Treatment in adults
Zanamivir as treatment is not associated with increased
adverse events of any type compared with placebo [1].
Table 1. Safety outcomes for oral oseltamivir used for prophylaxis in adults.
Dose and adverse 
outcome
Number of trials Oseltamivir group
n/N (%)
Placebo group
n/N (%)
Odds ratio
(95% CI)
P-value
75 mg/day
Nausea 2 [5,6] 71/675 (10.5) 23/413 (5.6) 1.8 (1.1 – 2.9) 0.02
Vomiting 2 [5,6] 20/675 (3.0) 6/413 (1.5) 2.3 (0.9 – 6.0) 0.09
Diarrhoea 1 [5] 13/155 (8.4) 21/153 (13.7) 0.6 (0.3 – 1.2) 0.14
Abdominal pain 1 [5] 18/155 (11.6) 18/153 (11.8) 1.0 (0.5 – 2.0) 0.97
Other adverse events 1 [5] 46/155 (29.7) 47/153 (30.7) 1.0 (0.6 – 1.6) 0.84
150 mg/day
Nausea 1 [5] 76/520 (14.6) 18/259 (6.9) 2.3 (1.3 – 3.9) 0.002
Vomiting 1 [5] 14/520 (2.7) 2/260 (0.8) 3.6 (0.8 – 15.8) 0.09
Table 2. Safety outcomes for oral oseltamivir (150 mg/day) used as treatment (adults).
Safety outcome Number of trials Oseltamivir group
n/N (%)
Placebo group
n/N (%)
Odds ratio 
(95% CI)
P-value
Cough* 1 [7] 125/134 (93.3) 127/139 (91.4) 1.3 (0.5 – 3.2) 0.55
Headache* 1 [7] 119/134 (88.8) 124/139 (89.2) 1.0 (0.5 – 2.0) 0.92
Diarrhoea 1 [8] 14/154 (9.1) 24/159 (15.1) 0.6 (0.3 – 1.1) 0.11
Nasal symptoms* 1 [7] 93/134 (69.4) 101/139 (72.7) 0.9 (0.5 – 1.4) 0.55
Nausea 2 [8,9] 91/565 (16.1) 31/363 (8.5) 1.8 (0.7, 4.4) 0.20
All adverse events 1 [8] 71/154 (46.1) 89/159 (56.0) 0.7 (0.4 – 1.1) 0.08
*Based on a symptom severity score of ≥ 1, where 0 = no symptom, 1 = minor, 2 = moderate, 3 = severe.
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A detailed breakdown of the various adverse events reported
is as follows: cough (OR: 1.4,  95% CI: 0.1 – 13.5), head-
ache (OR: 0.9,  95% CI: 0.4 – 2.0), diarrhoea (OR: 0.8,
95% CI: 0.4 – 1.6), nasal symptoms (congestion, rhinitis,
dry or sore throat) (OR: 1.0,  95% CI: 0.5 – 2.0), nausea
(OR: 0.6,  95% CI: 0.4 – 1.1), bronchitis or pneumonia
(OR: 0.7,  95% CI: 0.2 – 2.3) and all types of adverse events
(OR: 0.9,  95% CI: 0.7 – 1.1), Table 4.
3.3 Treatment in children
Zanamivir to treat children is not associated with increased
adverse events in comparison with placebo [2]. However, this
finding is based on data from just one study. Adverse
events, and serious adverse events, were similar OR = 0.8,
(95% CI: 0.5 – 1.2), and OR = 3.3 (95% CI: 0.1 – 8.2),
respectively, Table 4. Adverse events leading to study with-
drawal could not be assessed reliably because they were
reported so infrequently.
4. Conclusion
These data on neuraminidase inhibitors are somewhat limited
by limited good quality adverse event data available. The
majority of safety outcomes are based on evidence from just
one or two randomised, controlled trials. Consequently,
95% confidence intervals are wide and do not rule out the
possibility of clinically important adverse events from these
drugs in addition to those reported here.
Oseltamivir administered as prophylaxis in healthy adults
was associated with increased nausea. The causal effect is sup-
ported by the dose response: there was more nausea with a
greater dose of drug, so that for 75 mg/day, 20 patients had to
be treated to cause one to experience nausea, compared with
13 if they took double that dose. However, there was no sig-
nificant increase in vomiting. This might have been a conse-
quence of inadequate power: the incidence of vomiting was
lower than that for nausea. Nor was oseltamivir administered
Table 3. Safety outcomes for oral oseltamivir used as treatment (children).
Safety outcome Number of trials Oseltamivir group
n/N (%)
Placebo group
n/N (%)
Odds ratio (95% 
CI)
P-value
Any adverse event 2 [10,11] 251/514 (48.8) 269/515 (52.2) 0.9 (0.7 – 1.1) 0.3
Serious adverse 
events
2 [10,11] 8/514 (1.6) 4/515 (0.8) 2.0 (0.6 – 6.7) 0.3
Adverse events 
leading to study 
withdrawal
2 [10,11] 8/514 (1.6) 8/515 (1.6) 1.0 (0.4 – 2.7) 1
Nausea 2 [10,11] 17/514 (3.3) 22/515 (4.3) 0.8 (0.4 – 1.5) 0.4
Vomiting 2 [10,11] 76/514 (14.8) 48/515 (9.3) 1.2 (1.1 – 2.5) 0.008
Diarrhoea 2 [10,11] 40/514 (7.8) 49/514 (9.5) 0.8 (0.5 – 1.3) 0.3
Table 4. Safety outcomes for zanamivir in a treatment role in adults and children.
Age group,
Safety outcome
Number of trials Zanamivir group
n/N (%)
Placebo group
n/N (%)
Odds ratio (95% 
CI)
P-value
Adults
Cough 2 [12,13] 12/520 (2.3) 14/523 (2.7) 1.4 (0.1 – 13.5) 0.77
Headache 2 [14,15] 16/891 (1.8) 9/461 (2.0) 0.9 (0.4 – 2.0) 0.74
Diarrhoea 4 [12-15] 37/1431 (2.6) 28/984 (2.8) 0.8 (0.4 – 1.6) 0.51
Nasal symptoms 3 [12,13,15] 63/1354 (4.7) 61/945 (6.5) 1.0 (0.5 – 2.0) 0.95
Nausea 3 [12,15,16] 27/1235 (2.2) 28/832 (3.4) 0.6 (0.4 – 1.1) 0.10
Bronchitis or 
pneumonia
3 [12,13,15] 25/1354 (1.8) 30/945 (3.2) 0.7 (0.2 – 2.3) 0.59
All adverse events 3 [12,13,15] 181/597 (30.3) 187/562 (33.3) 0.9 (0.7 – 1.1) 0.34
Children
Any adverse event 1 [17] 48/224 (21.4) 65/247 (26.3) 0.8 (0.5 – 1.2) 0.3
Serious adverse 
events
1 [17] 1/224 (0.4) 0/247 (0.0) 3.3 (0.1 – 82.0) 0.3
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as prophylaxis at 75 mg daily in healthy adults associated
with diarrhoea, abdominal pain or other adverse events.
Data for these adverse outcomes were not available for
the increased dose of 150 mg daily or for administration to
children prophylactically.
Oseltamivir administered as treatment for adults was not
associated with cough, headache, diarrhoea, nasal symptoms or
nausea. An analysis of all adverse events combined also showed
no difference between patients given oseltamivir and patients
given placebo. However, all of these results, with the exception
of nausea, are based on just one study of ∼ 300 patients.
The odds ratio obtained for the nausea comparison was con-
sistent with the prophylaxis result, although there was no sta-
tistical significant difference found. In the case of children,
oseltamivir administered for treatment of influenza leads to an
increase in vomiting, where an additional 18 children treated
would result in one additional case of vomiting. Paradoxically
no increase in nausea was found, although this might be a
reporting anomaly: the overall incidence of vomiting reported
was much higher compared with that for nausea.
Oseltamivir was not associated with diarrhoea, serious
adverse events or adverse events serious enough to warrant
withdrawal from a randomised clinical trial. A comparison of
any adverse event also showed no difference between groups
of children treated with oseltamivir and equivalent groups
treated with placebo.
Zanamivir used as a prophylaxis against influenza in
healthy adults seemed to have no adverse effects. There are no
data for children. As treatment in adults, it was not associated
with cough, headache, diarrhoea, nasal symptoms, nausea,
bronchitis or pneumonia, nor all adverse events combined.
The data on which these conclusions are based are more sub-
stantial than for oseltamivir and so one might have more con-
fidence in them. They are based on between two and four
randomised studies and between 1000 and > 2000 patients in
total. In the case of children, treatment with zanamivir was
not associated with any adverse event or serious
adverse events, although the data on serious adverse events is
nonetheless limited.
5. Expert opinion
These drugs have a reasonable side effect and adverse effect
profile if they are to be used to treat or protect patients
against a life-threatening disease. However, if neuraminidase
inhibitors are to be prescribed in situations in which avoid-
ance of inconvenience or minor discomfort is hoped for, then
the balance of harms to benefits will be more difficult to
judge. One might expect zanamivir to have fewer systemic
side effects since it is inhaled rather taken systematically,
and this is supported by the data.
Can we expect more trials to supplement and better inform
these conclusions? First, potential trialists would have to con-
vince ethics committees that there is sufficient uncertainty
about the cost–benefit of the drugs in prophylaxis and treat-
ment of influenza to approve further work. Another source of
data might come from use of these drugs for other diseases,
such as H5N1 disease (the human form of avian influenza),
for which they are currently recommended [108]. Another
again would come from widespread use of the drug and obser-
vational data, often the source of rare or uncommon adverse
events of drugs.
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